Get the Stockscreener App
3.22
6.27%
0.19
After Hours:
3.08
-0.14
-4.35%
Onconetix Inc stock is traded at $3.22, with a volume of 441.05K.
It is up +6.27% in the last 24 hours and down -2.42% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
See More
Previous Close:
$3.03
Open:
$3.06
24h Volume:
441.05K
Relative Volume:
6.20
Market Cap:
$11.54M
Revenue:
$815.40K
Net Income/Loss:
$-14.03M
P/E Ratio:
-0.0122
EPS:
-264.0465
Net Cash Flow:
$-9.68M
1W Performance:
+33.36%
1M Performance:
-2.42%
6M Performance:
-81.00%
1Y Performance:
-92.85%
1-Day Range:
$2.755
$3.89
1-Week Range:
$2.257
$3.89
52-Week Range:
$2.1975
$74.29
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
3.22 | 10.86M | 815.40K | -14.03M | -9.68M | -264.05 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Onconetix Inc Stock (ONCO) Latest News
Long term debt to total equity ratio of Onconetix Inc – FWB:J4T1 - TradingView
Onconetix Inc Income Statement – FWB:J4T1 - TradingView
Onconetix Inc Financial Statements – FWB:J4T1 - TradingView
Onconetix Inc Balance Sheet – FWB:J4T1 - TradingView
Onconetix Inc Earnings and Revenue – FWB:J4T1 - TradingView
Tangible book value per share of Onconetix Inc – FWB:J4T1 - TradingView
After tax other income/expense of Onconetix Inc – FWB:J4T1 - TradingView
Total operating expenses of Onconetix Inc – FWB:J4T1 - TradingView
Onconetix Inc Cash Flow – FWB:J4T1 - TradingView
Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration - marketscreener.com
Number of employees of Onconetix Inc – FWB:J4T1 - TradingView
EBITDA margin % of Onconetix Inc – FWB:J4T1 - TradingView
EBIT per share of Onconetix Inc – FWB:J4T1 - TradingView
Onconetix (FRA:J4T1) Cyclically Adjusted Price-to-FCF : (As of Mar. 26, 2026) - GuruFocus
Onconetix announces 1-for-5 reverse stock split - MSN
Ericsson 6G Trial Features Realbotix Robot; Onconetix (NASDAQ: ONCO) to Acquire - Stock Titan
Onconetix (ONCO) formalizes new CEO deal and reshapes its board - Stock Titan
Cincinnati public firm names CEO, its fifth in two years, amid acquisition news - The Business Journals
Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration - The Manila Times
Realbotix Humanoid Robot Showcased in Ericsson's 6G Trial as Onconetix Moves to Acquire Realbotix Corp. - Quiver Quantitative
Onconetix, Inc. Appoints David White as Chief Executive Officer – March 2026 SEC 8-K Filing - Minichart
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split - Sahm
Onconetix Appoints New CEO and Refreshes Board Leadership - TipRanks
Onconetix On March 18 Appointed David White As CEO, Effective As Of That Date - TradingView
Onconetix names David White as CEO; Sammy Dorf joins board as Timothy Ramdeen resigns - TradingView
New CEO and board reshuffle at Onconetix (NASDAQ: ONCO) - Stock Titan
Onconetix approves 1-for-5 reverse stock split effective March 25 - Investing.com Canada
Onconetix approves 1-for-5 reverse stock split effective March 25 By Investing.com - Investing.com South Africa
Onconetix, Inc. announces 1-for-5 reverse stock split - marketscreener.com
Onconetix, Inc. Approves 1-for-5 Reverse Stock Split Effective March 25, 2026 - Quiver Quantitative
If You Invested $1,000 in Onconetix (ONCO) - Stock Titan
Onconetix, Inc. (ONCO) Competitors - Meyka
Onconetix (ONCO) asks shareholders to OK 1-for-2 to 1-for-10 reverse split - Stock Titan
Growth Review: Is Onconetix Inc stock a good dividend stock2026 Breakouts & Daily Price Action Insights - baoquankhu1.vn
ONCO Stock Price, Quote & Chart | ONCONETIX INC (NASDAQ:ONCO) - ChartMill
Onconetix (Formerly Blue Water Vaccines) Pursues Proclarix Commercialization and Realbotix Acquisition for Growth in Men’s Health and Oncology Diagnostics 25293041 - Minichart
Onconetix 2025 10-K: Revenue $0.82M, EPS $(16.56) - TradingView
ONCO: Net loss narrowed in 2025, but liquidity and going concern risks persist amid ongoing reliance on Proclarix - TradingView
Onconetix (NASDAQ: ONCO) 10-K flags going concern risk and major Realbotix reverse merger - Stock Titan
Onconetix, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug PreEarnings: Is Onconetix Inc forming a double bottom2026 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
Short Interest in Onconetix Drops by 76.1% - National Today
Buyout Rumor: How does Onconetix Inc perform in inflationary periodsMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Trend Report: Why is Onconetix Inc stock going downJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Swing Trade: What is the long term forecast for Onconetix Inc stockJuly 2025 Drop Watch & Breakout Confirmation Alerts - baoquankhu1.vn
ONCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sentiment Recap: Can Onconetix Inc reach all time highs this yearExit Point & Safe Entry Zone Identification - baoquankhu1.vn
Chipmakers Recap: How does AVNS perform in inflationary periodsJuly 2025 Closing Moves & Fast Moving Stock Watchlists - baoquankhu1.vn
Onconetix, Inc. (NASDAQ:ONCO) Short Interest Down 13.9% in January - Defense World
Why is Onconetix Inc. stock going down2025 Major Catalysts & High Accuracy Swing Entry Alerts - mfd.ru
Aug Rallies: What is the long term forecast for Onconetix Inc. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - mfd.ru
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):